宿主基因多态性对儿童灭活流感疫苗反应的影响。

Impact of host genetic polymorphisms on response to inactivated influenza vaccine in children.

作者信息

Tsang Tim K, Wang Can, Tsang Nicole N Y, Fang Vicky J, Perera Ranawaka A P M, Malik Peiris J S, Leung Gabriel M, Cowling Benjamin J, Ip Dennis K M

机构信息

WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.

Laboratory of Data Discovery for Health Limited, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China.

出版信息

NPJ Vaccines. 2023 Feb 20;8(1):21. doi: 10.1038/s41541-023-00621-1.

DOI:10.1038/s41541-023-00621-1

PMID:36804941

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9940051/

Abstract

In randomized controlled trials of influenza vaccination, 550 children received trivalent-inactivated influenza vaccine, permitting us to explore relationship between vaccine response and host single nucleotide polymorphisms (SNPs) in 23 candidate genes with adjustment of multiple testing. For host SNPs in TLR7-1817G/T (rs5741880), genotype GT was associated with lower odds (OR: 0.22, 95% CI: 0.09, 0.53) of have post-vaccination hemagglutination-inhibiting (HAI) titers ≥40, compared with genotype GG and TT combined under the over-dominant model. For host SNPs in TLR8-129G/C (rs3764879), genotype GT was associated with lower odds (OR: 0.47; 95% CI: 0.28, 0.80) of have post vaccination HAI titers ≥40 compared with genotype GG and AA combined under the over-dominant model. Our results could contribute to the development of better vaccines that may offer improved protection to all recipients.

摘要

在流感疫苗接种的随机对照试验中，550名儿童接种了三价灭活流感疫苗，这使我们能够在对多重检验进行校正的情况下，探索23个候选基因中疫苗反应与宿主单核苷酸多态性（SNP）之间的关系。对于Toll样受体7（TLR7）-1817G/T（rs5741880）位点的宿主SNP，在超显性模型下，与基因型GG和TT合并相比，基因型GT的接种后血凝抑制（HAI）滴度≥40的几率较低（比值比：0.22，95%置信区间：0.09，0.53）。对于Toll样受体8（TLR8）-129G/C（rs3764879）位点的宿主SNP，在超显性模型下，与基因型GG和AA合并相比，基因型GT的接种后HAI滴度≥40的几率较低（比值比：0.47；95%置信区间：0.28，0.80）。我们的结果可能有助于开发出能为所有接种者提供更好保护的更优疫苗。